Company Encyclopedia
View More
name
DAWNRAYS PHARMA
02348.HK
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates through two segments, Intermediates and Bulk Medicines; and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, cephalosporin tablets, and other oral solid-dosage-form antibiotics. It also provides system specific medicines comprising cardiovascular systems; anti-HBV, anti-allergic, and digestive systems; urinary systems; anti-hypertensive, antihyperlipidemic, and antiviral; and endocrine system drugs in the form of tablets, capsules, and granules.
1.450 T
02348.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking31/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.37%C
    • Profit Margin15.85%A
    • Gross Margin45.96%B
  • Growth ScoreC
    • Revenue YoY3.37%C
    • Net Profit YoY-68.61%E
    • Total Assets YoY-2.22%D
    • Net Assets YoY2.85%C
  • Cash ScoreC
    • Cash Flow Margin630.88%C
    • OCF YoY3.37%C
  • Operating ScoreD
    • Turnover0.28D
  • Debt ScoreA
    • Gearing Ratio14.93%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zhitong Hong Kong Stock Investment Journal | October 3

    On October 3, 2025, the investment log of Hong Kong listed companies is as follows: Category | Company --- | --- New Share Activities | ZhiDa Technology (in IPO) | Golden Leaf International Group (in IPO) Earnings Announcement Date | Polyfair Holdings Shareholders Meeting Date | Postal Savings Bank | Japan Symbiosis | CHINA STARCH | TONGDA GROUP | Huayin International Holdings | QPL INT'L Dividends | Giordano International (dividend date) | Datang New Energy (ex-dividend date) | China Overseas Development (dividend date) | Lee's Pharmaceutical (dividend date) | Dali International (dividend date) | RAYMOND IND (dividend date) | DAWNRAYS PHARMA (dividend date) | Tianbao Group (ex-dividend date) | Q Technology (ex-dividend date) | AV CONCEPT HOLD (dividend date) | King Fook Holdings (dividend date) | Huaxin Real Estate Finance (dividend date) | Changjiang Garment (ex-dividend date) | YGM TRADING (ex-dividend date) | New Baoli Financing (ex-dividend date) | Anxian Garden China (dividend date) | Li Bao (dividend date)

    Zhitong·
    HK
    03838
    0.00%
    HK
    00229
    -2.06%
    HK
    08532
    -9.09%
    Zhitong·
    HK
    03838
    0.00%
    HK
    00229
    -2.06%
    HK
    08532
    -9.09%

    "Performance" DAWNRAYS PHARMA's mid-term net profit is 105 million RMB, down 78.8%, with a dividend of 1.5 HK cents

    DAWNRAYS PHARMA announced its interim results for the six months ended June, with revenue of RMB 630 million, a year-on-year decrease of 9.2%. It recorded a net profit of RMB 105 million, a decline of 78.8%, with earnings per share of 6.961 cents. The interim dividend remains at 1.5 HK cents

    AASTOCKS·
    HK
    02348
    +0.81%
    AASTOCKS·
    HK
    02348
    +0.81%

    DAWNRAYS PHARMA announced its interim results, with a profit attributable to the parent company owners of approximately 105 million yuan, a year-on-year decrease of 78.79%

    DAWNRAYS PHARMA announced its mid-year results for 2025, with a profit attributable to the parent company of approximately 105 million yuan, a year-on-year decrease of 78.79%. Revenue was approximately 630 million yuan, a year-on-year increase of 9.2%; gross profit was approximately 314 million yuan, a year-on-year decrease of 7.1%. In terms of sales, the sales volume of the antihypertensive "An" series products decreased by 5.7%, and sales revenue fell by 22.1%. The sales volume of the antiviral drug Entecavir dispersible tablets increased by 14.0%, and sales revenue grew by 8.7%. The overall profit decline was mainly due to the new factory not achieving scaled production, policy impacts, and increased R&D expenses

    Zhitong·
    HK
    02348
    +0.81%
    Zhitong·
    HK
    02348
    +0.81%

    DAWNRAYS PHARMA: Hu Shuo has been appointed as a non-executive director

    According to the Zhitong Finance APP, DAWNRAYS PHARMA announced that Mr. Hu Shuo has been appointed as a non-executive director of the company, effective from August 1, 2025

    Zhitong·
    HK
    02348
    +0.81%
    Zhitong·
    HK
    02348
    +0.81%

    Seiko International Steel Structure Co., Ltd. increased its holdings in DAWNRAYS PHARMA by 109 million shares at a price of HKD 1.20 per share

    According to the latest data from the Hong Kong Stock Exchange, on July 3rd, Jinggong International Steel Structure Co., Ltd. increased its holdings in DAWNRAYS PHARMA by 109 million shares, at a price of HKD 1.2 per share, totaling approximately HKD 130.8 million. After the increase, the latest number of shares held is 109 million, with a shareholding ratio of 7.24%. This transaction involves other related parties: Changjiang Jinggong Steel Structure (Group) Co., Ltd

    Zhitong·
    HK
    02348
    +0.81%
    Zhitong·
    HK
    02348
    +0.81%
    © 2025 Longbridge｜Disclaimer